SCHEMBL20116420

SCHEMBL20116420

COC1(C(=O)N2CCC(c3noc(-c4ccc5cnn(C6COC6)c5c4)n3)CC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
SMO Q99835 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.38
USP30 Q70CQ3 3/20 0.37
HTT P42858 1/20 0.36
PIK3CD O00329 2/20 0.35
KIT P10721 1/20 0.35
TBK1 Q9UHD2 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
IDO1 P14902 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
WNT1 P04628 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116089 0.91 SMO (0.42) USP7SMN1; SMN2SMOKDM4ENPC1
SCHEMBL20116423 0.88 FASN (0.43) USP7SMN1; SMN2SMOUSP30HTT
SCHEMBL22358068 0.88 USP7 (0.38) USP7SMN1; SMN2SMOKDM4ENPC1
SCHEMBL20116243 0.88 KDM4E (0.42) USP7SMN1; SMN2SMOKDM4ENPC1
SCHEMBL20116172 0.87 USP7 (0.38) USP7SMN1; SMN2USP30HTTPIK3CD
SCHEMBL20116391 0.87 FASN (0.35) NPC1USP30HTTPIK3CDLMNA
SCHEMBL20117083 0.87 USP7 (0.39) USP7SMN1; SMN2SMOUSP30HTT
SCHEMBL20116041 0.86 GPR119 (0.49) USP7USP30TBK1GPR119
SCHEMBL20676596 0.86 USP30 (0.37) USP7SMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL20116521 0.86 USP7 (0.38) USP7SMN1; SMN2SMOALDH1A1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 USP7 4265/4885SMN1; SMN2 13/4885SMO 1858/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 USP7 4265/4885SMN1; SMN2 13/4885SMO 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.